Seeking Alpha
 

CEPHEID (CPHD)

- NASDAQ
Show Summaries  |  Hide Summaries
  • Jul. 18, 2014, 12:45 PM
    | Comment!
  • Jul. 17, 2014, 5:35 PM
    | 1 Comment
  • Jan. 31, 2014, 12:46 PM
    | Comment!
  • Jan. 30, 2014, 5:36 PM
    | 7 Comments
  • Jan. 30, 2014, 4:14 PM
  • Oct. 17, 2013, 5:42 PM
    | 6 Comments
  • Oct. 17, 2013, 4:23 PM
    | Comment!
  • Oct. 4, 2013, 12:09 PM
    | Comment!
  • Jul. 19, 2013, 5:32 PM
    After-hours top gainers, as of 5:15 p.m.: DRIV +3%. CYT +2%. SRC +2%. STAG +1%. PBI +1%.
    After-hours top losers: EPOL -4%. CPHD -4%. TSYS -3%. FLOW -3%. CYH -3%.
    | 1 Comment
  • Jul. 11, 2013, 4:21 PM
    Cepheid (CPHD) reports preliminary Q2 results: GAAP net loss of $0.10/ share and non-GAAP net income of $0.02/ share on revenue of ~$96M. CEO John Bishop says "record revenue and associated production volume" show the company made "good progress" on allaying investor concerns regarding Xpert test availability. Shares +2.7% AH. (PR)
    | Comment!
  • Jun. 26, 2013, 10:53 AM
    Cepheid (CPHD +3.4%) moves up today after coverage is resumed at Oppenheimer with an Outperform and a $41 price target.
    | Comment!
  • May 31, 2013, 3:52 PM
    Cepheid (CPHD -4.4%) slides after Jefferies analyst Brandon Couillard assumes coverage of the shares with a downgrade to Hold, but reiterates the $38 price target. Couillard says that the company is well-positioned for margin expansion over the longer term as it leverages investments in its R&D pipeline, launches new high-margined tests and captures greater manufacturing efficiencies, but present valuations are already reflecting these bullish growth expectations.
    | Comment!
  • Apr. 18, 2013, 5:53 PM
    After-hours top gainers, as of 5:15 p.m.: RH +8%. IMRS +6%. BGS +5%. CPHD +5%. PRLB +5%.
    After-hours top losers: AIRM -15%. CIE -6%. LSCC -5%. AMD -5%. TAHO -4%.
    | Comment!
  • Jan. 24, 2013, 5:42 PM
    After-hours top gainers, as of 5:15 p.m.: TPX +18%. INFA +12%. RMD +6%. KLAC +3%. QIHU +3%.
    After-hours top losers: SCSS -17%. FLEX -7%. SFL -6%. ETFC -5%. CPHD -4%.
    | Comment!
  • Jan. 8, 2013, 12:42 PM
    Cepheid (CPHD +5.2%) ramps higher after reporting preliminary Q4 results, saying its EPS should come in just above its prior guidance of $0.10 to $0.12 a share due to a favorable revenue mix. Analysts have been expecting a $0.02 per share net loss for the quarter. Revenue is expected to be below its prior view however, driven by weaker clinical revenue from high-burden developing countries
    | Comment!
  • Jan. 4, 2013, 12:14 PM
    Cepheid (CPHD -1.8%) slips on a downgrade to Neutral at Piper Jaffray on concerns that Q4 results and its FY13 outlook could both miss expectations. The company suffered two manufacturing glitches in FY12 that impacted its ability to meet customer cartridge demand in Q3. This created a backlog and the need to put accounts on allocation as management resolved the issue. Piper thinks CPHD may have missed its end of November allocation target. The firm also cut its price target to $34 from $42.
    | Comment!
Visit Seeking Alpha's
CPHD vs. ETF Alternatives
Company Description
Cepheid is a molecular diagnostics company that develops, manufactures and markets integrated systems for testing in the clinical market, as well as for application in its non-clinical market.